These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23333884)

  • 1. Solid lipid based nanocarriers: an overview.
    Pardeshi C; Rajput P; Belgamwar V; Tekade A; Patil G; Chaudhary K; Sonje A
    Acta Pharm; 2012 Dec; 62(4):433-72. PubMed ID: 23333884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance.
    Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
    Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
    Garg A; Singh S
    Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems.
    Uner M
    Pharmazie; 2006 May; 61(5):375-86. PubMed ID: 16724531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug targeting using solid lipid nanoparticles.
    Rostami E; Kashanian S; Azandaryani AH; Faramarzi H; Dolatabadi JE; Omidfar K
    Chem Phys Lipids; 2014 Jul; 181():56-61. PubMed ID: 24717692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.
    Silva AC; Kumar A; Wild W; Ferreira D; Santos D; Forbes B
    Int J Pharm; 2012 Oct; 436(1-2):798-805. PubMed ID: 22867992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake.
    Luo Y; Teng Z; Li Y; Wang Q
    Carbohydr Polym; 2015 May; 122():221-9. PubMed ID: 25817662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo real-time fluorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester:oil ratios.
    Wen CJ; Yen TC; Al-Suwayeh SA; Chang HW; Fang JY
    Nanomedicine (Lond); 2011 Nov; 6(9):1545-59. PubMed ID: 22077462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.
    Huang ZR; Hua SC; Yang YL; Fang JY
    Acta Pharmacol Sin; 2008 Sep; 29(9):1094-102. PubMed ID: 18718178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid lipid nanoparticles: promising therapeutic nanocarriers for drug delivery.
    Thukral DK; Dumoga S; Mishra AK
    Curr Drug Deliv; 2014; 11(6):771-91. PubMed ID: 25469779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery.
    Liu CH; Wu CT; Fang JY
    Drug Dev Ind Pharm; 2010 Jul; 36(7):751-61. PubMed ID: 20136495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery.
    Date AA; Vador N; Jagtap A; Nagarsenker MS
    Nanotechnology; 2011 Jul; 22(27):275102. PubMed ID: 21606564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid lipid nanoparticles for parenteral drug delivery.
    Wissing SA; Kayser O; Müller RH
    Adv Drug Deliv Rev; 2004 May; 56(9):1257-72. PubMed ID: 15109768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLN for topical application in skin diseases--characterization of drug-carrier and carrier-target interactions.
    Küchler S; Herrmann W; Panek-Minkin G; Blaschke T; Zoschke C; Kramer KD; Bittl R; Schäfer-Korting M
    Int J Pharm; 2010 May; 390(2):225-33. PubMed ID: 20153414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of solid lipid nanoparticles for sustained drug release.
    Attama AA; Umeyor CE
    Ther Deliv; 2015; 6(6):669-84. PubMed ID: 26149784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry.
    Castelli F; Puglia C; Sarpietro MG; Rizza L; Bonina F
    Int J Pharm; 2005 Nov; 304(1-2):231-8. PubMed ID: 16188405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin.
    Ridolfi DM; Marcato PD; Justo GZ; Cordi L; Machado D; Durán N
    Colloids Surf B Biointerfaces; 2012 May; 93():36-40. PubMed ID: 22244299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid nanoparticles for parenteral delivery of actives.
    Joshi MD; Müller RH
    Eur J Pharm Biopharm; 2009 Feb; 71(2):161-72. PubMed ID: 18824097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of lipid excipients in solid lipid nanoparticles.
    Radomska-Soukharev A
    Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review.
    Garcês A; Amaral MH; Sousa Lobo JM; Silva AC
    Eur J Pharm Sci; 2018 Jan; 112():159-167. PubMed ID: 29183800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.